Even with the neuroimaging agent that targets SV2A in the brain for synaptic density assessment but not SV2A in NEPC for oncological imaging [41,51], we were able to clearly visualize the SV2A+ tumors and confirm the desired SV2A-imaging specificity (Figure 4) for noninvasive assessment of NED in NEPC or other innervated cancer types. This evidence concerns the gene SV2A and cancer.